RxDoctor Payments Data

Edwin Kase, MD

Internal Medicine · Lebanon, PANPI 1619969144

Payments from drug & device makers

$332in general payments, 2019–2025

Across 19 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$199
  • Tactile Systems Technology Inc$97
  • Pfizer$36

What the payments were for

  • Food & beverage$332100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk11$199
Tactile Systems Technology Inc6$97
Pfizer2$36

How this compares

$332 in reported general payments places this provider in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$300,318
Medicare patients
580
Services billed
8,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban224$193,815
JardianceEmpagliflozin89$79,530
OzempicSemaglutide39$55,576
XareltoRivaroxaban55$52,127
RybelsusSemaglutide22$26,638
JanuviaSitagliptin Phosphate30$22,243
Spiriva RespimatTiotropium Bromide16$16,050
Breo ElliptaFluticasone/Vilanterol31$13,861
MounjaroTirzepatide13$13,624
Atorvastatin Calcium948$11,036
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,702
Aspirin-Dipyridamole ErAspirin/Dipyridamole21$8,923
Omeprazole376$4,891
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$4,592
Lisinopril511$4,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$193,815224 claims
Novo NordiskOzempic, Rybelsus$199$82,21461 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Lebanon

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →